摘要
目的探讨类风湿关节炎(RA)患者外周血单个核细胞(PBMC)中miR146a及miR155的表达与益赛普治疗RA疗效的相关性。方法 117例中国RA患者接受了为期3个月的益赛普治疗,以欧洲抗风湿病联盟与美国风湿病学学会共同修订的RA临床缓解新标准评估益赛普对RA的疗效。采用实时荧光定量逆转录聚合酶链反应法检测PBMC中miR146a及miR155的表达水平,并分析miR146a及miR155的表达水平与益赛普治疗RA疗效的相关性。结果治疗后,临床缓解91例,26例患者未达到临床缓解新标准。临床缓解患者PBMC中miR146a的表达水平显著低于未达到临床缓解患者[(1.30±0.62)比(1.59±0.56),P<0.05],而两组患者miR155的表达水平无显著性差异[(1.87±0.46)比(1.83±0.33),P>0.05]。结论治疗前,PBMC中miR146a的表达水平与益赛普治疗RA的疗效可能相关,具有较低miR146a表达水平的RA患者对益赛普的疗效反应较好,有可能作为益赛普对RA的疗效预测指标,具体作用机制尚需作进一步研究。
Objective To investigate the correlation between the expression level of miR-146a and miR155 in peripheral blood mononuclear cells(PBMCs)in patients with rheumatoid arthritis(RA)and the effect of Yisaipu in the treatment of RA.Methods Totally 117 patients with RA in China received the treatment of Yisaipu for 3 months,the clinical effect of Yisaipu in the treatment of RA was evaluated by new standard of ACR/EULAR definition of clinical remission in RA,the expression levels of miR-146a and miR155 in PBMCs of RA patients were determined by quantitative realtime RT-polymerase chain reaction(RT-PCR),the correlation between the expression level of miR-146a and miR155 and the effect of Yisaipu in the treatment of RA was analyzed.Results After treat-ment,91 patients cases were remission,and 26 patients failed to meet the new standard of clinical remission.The expression level of miR 146a in the PBMC of the patients with clinical remission was significantly lower than that of patients who failed to meet clinical remission[(1.30±0.62)vs.(1.59±0.56),P<0.05].However,there was no significant difference in the expression level of miR155 in the two groups[(1.87±0.46)vs.(1.83±0.33),P>0.05].Conclusion Before treatment,the expression level of miR146a in PBMCs may be related to the efficacy of Yisaipu in the treatment of RA,the RA patients with lower expression levels of miR146a have better effect response to Yisaipu,the expression level of miR146a may be used as a predictor of curative effect of Yisaipu on RA,and the specific mechanism needs further study.
作者
佘若男
李博
胡秋侠
吴系美
谭锦辉
胡建云
唐群芳
汪小平
She Ruonan;Li Bo;Hu Qiuxia;Wu Ximei;Tan Jinhui;Hu Jianyun;Tang Qunfang;Wang Xiaoping(Department of Rheumatology,The People′s Hospital of Longhua District in Shenzhen City,Shenzhen,Guangdong,China 518109)
出处
《中国药业》
CAS
2018年第7期24-26,共3页
China Pharmaceuticals
基金
广东省医学科研基金立项课题[A2013611]
广东省深圳市卫生计生系统科研项目(医疗卫生类)[201501051]
广东省深圳市科技计划项目(医疗卫生类)[201601060]
广东省深圳市龙华区科技创新资金项目(医疗卫生类)[20150924A1030103]